Product Details
KEYTRUDA (pembrolizumab) 100 mg/4 ml Injection In Pakistan
KEYTRUDA (pembrolizumab) 100 mg/4 mL is an immunotherapy medicine containing pembrolizumab, a monoclonal antibody that blocks the PD-1 pathway. By blocking this pathway, KEYTRUDA can help the immune system recognize and attack certain cancer cells. It is used for several types of cancer depending on the patient's diagnosis, tumor characteristics, and treatment plan.
Benefits
- Helps activate the body's immune response against certain cancer cells.
- Used in the treatment of various cancers under specialist supervision.
- May be used alone or in combination with other cancer treatments, depending on the indication.
- Provides targeted immunotherapy through PD-1 pathway inhibition.
- Can be considered for eligible patients based on cancer type and relevant biomarker testing.
Specifications
- Brand Name: KEYTRUDA
- Active Ingredient: Pembrolizumab
- Strength: 100 mg/4 mL
- Concentration: 25 mg/mL
- Dosage Form: Solution for injection
- Route: Intravenous (IV) infusion
- Packaging: Single-dose vial
- Drug Class: PD-1 blocking monoclonal antibody
- Use: Cancer immunotherapy
- Storage: Follow the manufacturer's storage requirements; diluted solution has specific time and temperature limits. Do not freeze.
How To Use
KEYTRUDA 100 mg/4 mL is administered intravenously by a qualified healthcare professional. The appropriate dose and treatment interval depend on the cancer type, treatment regimen, patient's age/weight where applicable, and medical condition. Standard IV administration is given over approximately 30 minutes.
Do not self-administer KEYTRUDA or change the prescribed treatment schedule. Your oncologist should determine the appropriate treatment plan and monitor you for possible immune-related adverse reactions.
Why Choose KEYTRUDA?
- Established immunotherapy containing pembrolizumab.
- Specifically targets the PD-1 immune-checkpoint pathway.
- Used across multiple cancer treatment settings.
- Available as a 100 mg/4 mL single-dose vial.
- Treatment can be tailored according to the patient's cancer type and clinical requirements.
